Pfizer announced this morning that the FDA has issued a Complete Response Letter for PF-05280014, a proposed trastuzumab biosimilar referencing Herceptin.
Pfizer announced this morning that the FDA has issued a Complete Response Letter (CRL) for PF-05280014, a proposed trastuzumab biosimilar referencing Herceptin.
The company says that the FDA highlighted the need for “additional technical information,” and that the agency did not request information related to safety or clinical data submitted in the Biologics License Application. Pfizer says that it is working closely with the FDA to address the letter’s contents and remains committed to developing the proposed product.
Pfizer presented positive results for PF-05280014 at the September 2017 meeting of the European Society for Medical Oncology; in the REFLECTIONS B327-02 study, the proposed biosimilar showed an equivalent objective response rate versus reference trastuzumab in patients receiving first-line treatment, in combination with paclitaxel, for HER2-positive metastatic breast cancer. The REFLECTIONS B327-04 study showed no clinically meaningful differences between the proposed biosimilar and the reference trastuzumab in terms of safety or immunogenicity, and noninferiority in pharmacokinetics.
Rejection of Pfizer’s trastuzumab candidate follows closely on the heels of another biosimilar trastuzumab’s rejection by the FDA; on April 5, Celltrion and Teva announced that the FDA had issued a CRL for their CT-P6, a decision that followed receipt a warning letter from the agency concerning manufacturing practices.
These 2 regulatory setbacks for biosimilar trastuzumab leave Mylan and Biocon’s Ogivri, which received the FDA’s approval 2017, as the only approved trastuzumab biosimilar in the United States. No launch date for Ogivri has yet been announced, however.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.